An Everest Group study across industries found that 48% of enterprise respondents are expecting to shift to a shared services or global business services (GBS) sourcing model.
Biopharma has been slow to adopt this model. However, as GBS transitions from capacity to capability centers and enterprises’ expectations from GBS evolves from cost productivity to augmenting technology capabilities and strategic process re-engineering, pharma GBS centers will increasingly partner with specialist service providers to augment and elevate inhouse capabilities.
